Charlottesville, VA – According to filings with the U.S. Securities and Exchange Commission, ZielBio is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kimberly Kelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ZielBio
By using a combination of wet lab screening, proprietary databases and sophisticated algorithms to screen cells for specific attributes to identify targets that could be associated with diseases, our Zielfind platform overcomes the limits of current drug discovery techniques.

To learn more about ZielBio, visit http://zielbio.com/

Contact:
Kimberly Kelly, Chief Executive Officer
434-202-7771
kkelly@zielbio.com
https://www.linkedin.com/in/kimberly-kelly-b8b8b0ba/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved